Eleftha 440mg Injection consists of Trastuzumab as an active constituent which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumor by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.
Anti Cancer, Anti Cancer Injections
Eleftha 440mg Injection
₹8,050.00
| Dosage Form | Concentrate |
|---|---|
| Treatment | Breast Cancer |
| Packaging Type | Vial |
| Brand | Eleftha |
| Manufacturer | Intas |
| Strength | 440 mg |
| Shelf Life | 48 months |
| Physical Form | Lyophilized Powder |
Reviews
There are no reviews yet.